EMPAGLIFLOZIN / LINAGLIPTIN (Glyxambi®)

Clinical Indication

Type 2 diabetes mellitus in adults

Comments

New formulation
Not yet reviewed

Date of classification

June 2017

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.